The recombinant protein market is fragmented with a diverse portfolio of biopharmaceutical drugs and services including hormones, cytokines, enzymes, blood factors and growth factors which are used in therapeutic areas including oncology, metabolism, hematology, infectious diseases, endocrinology and ophthalmology. The recombinant proteins offer advantages of high efficacy, low toxicity, and high specificity compared to conventional drugs. The recombinant protein drugs are used in the treatment of various life-threatening diseases such as hemophilia, cancer, and other diseases which has increased the demand in the recent years.

The Global recombinant protein market is estimated to be valued at US$ 3607.34 Bn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period from 2024 to 2031.

Key Takeaways
Key players operating in the Recombinant Protein Market Size are Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.). These key players operate globally and account for major market share.

The growing prevalence of chronic diseases such as cancer and diabetes along with rising geriatric population has increased the demand of recombinant protein-based drugs across the globe. Lack of therapeutic alternatives along with superior efficacy and safety of recombinant proteins have further increased the adoption rate. Moreover, rising healthcare expenditure in emerging economies is also aiding the market growth on the global front.

International organizations are also supporting efforts to accelerate research, development and commercialization of cost-effective recombinant protein drugs. Additionally, regulatory reforms across several countries have eased manufacturing and supply chain of biologics which has encouraged global expansion plans of market leaders. Overall growth of biopharmaceutical industry and improved access of biologics in developing regions are expanding global geographic footprint of recombinant protein market over the forecast period.

Market drivers
Advancements in cellular engineering and gene expression systems have reduced production cost and complexity of recombinant proteins over the last decade. Major players are actively investing in these R&D activities to develop novel affordable biosimilars. In addition, strategic collaborations between drug makers and contract development & manufacturing organizations are further enhancing cost efficiency of recombinant protein development and large scale manufacturing process. This key driver is expected to boost overall adoption of recombinant protein drugs going ahead.

Get more insights on Recombinant Protein Market